Positive new and updated data at ASCO for Rybrevant plus lazertinib could position the combo more strongly against Tagrisso in the first-line treatment of high-risk, EGFR-mutated non-small lung cancer. 

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

Scrip takes a look at major R&D trends in the Korean biotech sector in the third quarter, analysing new moves at Genexine, Bridge Biotherapeutics, Oscotec and others to cope with ongoing challenges and focus resources on the most promising projects.

Korean biopharma companies and the government are making diverse efforts to collaborate and seek growth to overcome limited resources and capital, as well as a tough investment environment.